Lucid Diagnostics Announced That The American Foregut Society Has Formally Requested That Health Insurance Providers Update Their Medical Policies To Include The EsoGuard Esophageal DNA Test As A Covered Service
Portfolio Pulse from Benzinga Newsdesk
Lucid Diagnostics announced that the American Foregut Society has formally requested health insurance providers to update their medical policies to include the EsoGuard Esophageal DNA test as a covered service. This aims to enhance early detection and treatment of esophageal precancer.
August 13, 2024 | 12:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lucid Diagnostics may see a positive impact as the American Foregut Society has requested insurance coverage for its EsoGuard Esophageal DNA test, potentially increasing its adoption and revenue.
The formal request by a leading medical society for insurance coverage of Lucid's EsoGuard test could lead to higher adoption rates and increased revenue, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
PAVmed Inc., the parent company of Lucid Diagnostics, may also benefit indirectly from the potential increase in adoption and revenue of the EsoGuard test.
As the parent company of Lucid Diagnostics, PAVmed Inc. stands to benefit from any positive financial impact resulting from increased adoption of the EsoGuard test.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 50